Location South San Francisco, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
William Lis joined Portola in 2008 and was appointed chief executive officer in May 2010. During this time Portola has executed a Series D financing, initiated a global pivotal Phase 3 trial for its lead program betrixaban, and advanced its Factor Xa inhibitor antidote and spleen tyrosine kinase inhibitor programs into clinical trials. Prior to
that, he served as chief operating officer and chief business officer, during which time Portola completed positive Phase 2 trials for elinogrel and betrixaban, executed a Series C financing, and executed two worldwide licensing agreements. He has more than 20 years of experience in biopharmaceutical sales and marketing, corporate development and management of operations. Prior to Portola, William Lis held positions at Scios, Inc. (a Johnson & Johnson Company) from 2003 to 2007, where he most recently served as vice president, business and new product development, responsible for cardiovascular business licensing and commercial operations. He led successful in-licensing activities and commercial launch activities for Xarelto® (rivaroxaban). Prior to Scios, he was senior director of marketing and new products for Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.), where he directed marketing activities for Integrilin® (eptifibatide). At Rhone-Poulenc Rorer, he was involved in the U.S. sales launch and commercialization of several products, including Lovenox® (enoxaparin). William Lis holds a B.S. in finance from the University of Maryland.
